Porownywarka

Octreotide vs Glucagon side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

OctreotideGlucagon

Udostępnij porównanie peptydów

Wlasciwosc	Octreotide	Glucagon
Kategoria	Hormonalne	Hormonalne
Znany tez jako	Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa	GlucaGen, Baqsimi
Zatwierdzony przez FDA	Tak	Tak
Status kliniczny	FDA Approved - Multiple indications Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	FDA Approved - Hypoglycemia and diagnostic Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Acromegaly, carcinoid tumors, hormone regulation	Hypoglycemia emergency, blood sugar rescue
Jak dziala	Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow.	Glucagon is reported to bind GCGR, a liver-focused G-protein-coupled receptor. Downstream signaling proceeds through Gs, adenylate cyclase, cAMP, and PKA. In the supplied mechanism description, this signaling promotes glycogenolysis and gluconeogenesis, including enzymes such as PEPCK and glucose-6-phosphatase, resulting in increased glucose release from the liver.
Typowe dawkowanie	100-500 mcg SC 2-3x daily or LAR monthly · 2-3x daily (SC) or monthly (LAR) · Subcutaneous or intramuscular depot	Limited community data available · See research protocols
Dawkowanie z badań	50-200 mcg SC 3x daily (immediate) · Long-term / chronic use · Subcutaneous or intramuscular depot	1 mg IM/SC/IV for hypoglycemia · Single dose emergency use · Injection, intranasal, or auto-injector
Typowy czas trwania	Long-term / chronic use	Single dose emergency use
Podanie	Subcutaneous injection, intramuscular depot, or oral capsule formulations are reported.	Injection, intranasal, or auto-injector
Timing	Morning or as directed With or without food	Morning Take on empty stomach
Poziom dowodów	Zatwierdzone przez FDA	Zatwierdzone przez FDA
Mozliwe skutki uboczne	Nausea Diarrhea Abdominal pain +5 więcej Gallstones (Source reports 52-63% with long-term use.) Bradycardia Hyperglycemia or hypoglycemia (Source lists blood glucose changes in either direction.) Hypothyroidism Pancreatitis	Nausea (Source reports nausea up to 35%.) Vomiting Headache +5 więcej Hypertension Tachycardia Allergic reactions Rebound hypoglycemia Contraindicated with pheochromocytoma (Source lists pheochromocytoma as a contraindication.)
Podsumowanie researchu	The supplied evidence characterizes Octreotide as a well-studied peptide drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar.	The supplied evidence presents glucagon as an established hormone and FDA-approved clinical agent rather than an experimental peptide. It notes severe hypoglycemia rescue as a settled use and describes newer formats such as nasal powder and stable liquid auto-injectors. Mechanistic research cited in the source centers on GCGR and PKA signaling control of hepatic glucose output. The source also links excess glucagon signaling with poorer glucose regulation in diabetes and notes current interest in GCGR activity within dual and triple metabolic agonist drug research.
Referencje	Źródło Źródło +2 więcej Źródło Źródło	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Octreotide

Glucagon

Kategoria

Hormonalne

Znany tez jako

Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa

GlucaGen, Baqsimi

Zatwierdzony przez FDA

Tak

Status kliniczny

FDA Approved - Multiple indications

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

FDA Approved - Hypoglycemia and diagnostic

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Acromegaly, carcinoid tumors, hormone regulation

Hypoglycemia emergency, blood sugar rescue

Jak dziala

Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow.

Glucagon is reported to bind GCGR, a liver-focused G-protein-coupled receptor. Downstream signaling proceeds through Gs, adenylate cyclase, cAMP, and PKA. In the supplied mechanism description, this signaling promotes glycogenolysis and gluconeogenesis, including enzymes such as PEPCK and glucose-6-phosphatase, resulting in increased glucose release from the liver.

Typowe dawkowanie

100-500 mcg SC 2-3x daily or LAR monthly · 2-3x daily (SC) or monthly (LAR) · Subcutaneous or intramuscular depot

Limited community data available · See research protocols

Dawkowanie z badań

50-200 mcg SC 3x daily (immediate) · Long-term / chronic use · Subcutaneous or intramuscular depot

1 mg IM/SC/IV for hypoglycemia · Single dose emergency use · Injection, intranasal, or auto-injector

Typowy czas trwania

Long-term / chronic use

Single dose emergency use

Podanie

Subcutaneous injection, intramuscular depot, or oral capsule formulations are reported.

Injection, intranasal, or auto-injector

Timing

Morning or as directed

With or without food

Morning

Take on empty stomach

Poziom dowodów

Zatwierdzone przez FDA

Mozliwe skutki uboczne

Nausea
Diarrhea
Abdominal pain

+5 więcej

Gallstones (Source reports 52-63% with long-term use.)
Bradycardia
Hyperglycemia or hypoglycemia (Source lists blood glucose changes in either direction.)
Hypothyroidism
Pancreatitis

Nausea (Source reports nausea up to 35%.)
Vomiting
Headache

+5 więcej

Hypertension
Tachycardia
Allergic reactions
Rebound hypoglycemia
Contraindicated with pheochromocytoma (Source lists pheochromocytoma as a contraindication.)

Podsumowanie researchu

The supplied evidence characterizes Octreotide as a well-studied peptide drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar.

The supplied evidence presents glucagon as an established hormone and FDA-approved clinical agent rather than an experimental peptide. It notes severe hypoglycemia rescue as a settled use and describes newer formats such as nasal powder and stable liquid auto-injectors. Mechanistic research cited in the source centers on GCGR and PKA signaling control of hepatic glucose output. The source also links excess glucagon signaling with poorer glucose regulation in diabetes and notes current interest in GCGR activity within dual and triple metabolic agonist drug research.

Referencje

+2 więcej

+2 więcej

Pełny profil